Teva

Latest stories

3h
KGTV San Diego
How to find a more affordable epipenmore about it below: 4. Generic EpiPen A generic EpiPen could become availabl
How to find a more affordable epipen
KGTV San Diego / Posted 3 hours ago
more about it below: 4. Generic EpiPen A generic EpiPen could become available, at earliest, in 2017. The manufacturer, Teva Pharmaceutical Industries, applied for FDA approval earlier this year and is currently addressing, per the FDA, “major... Read more
3h
Orlando Sentinel
How EpiPen's maker raised prices so much, and why it's made people furioushas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices so much, and why it's made people furious
Orlando Sentinel / Posted 3 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
4h
Newsmax
Clinton's Attacks on Drug Pricing Leave Health Stocks Reeling& Co. in New York. He mostly blamed the dip after Clinton’s statement to sensit
Clinton's Attacks on Drug Pricing Leave Health Stocks Reeling
Newsmax / Posted 4 hours ago
& Co. in New York. He mostly blamed the dip after Clinton’s statement to sensitivity surrounding health stocks generally. Teva Pharmaceutical Industries Ltd. is also working on a generic competitor that could benefit from a sped-up review as a... Read more
225 related stories
5h
Chicago Tribune
How EpiPen's maker raised prices so much, and why it's made people furioushas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices so much, and why it's made people furious
Chicago Tribune / Posted 5 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
5h
Fortune
Here's Why Mylan Has Something to Be Happy About TodayShares of Teva Pharmaceuticals Industries teva took a dip during trading hours
Here's Why Mylan Has Something to Be Happy About Today
Fortune / Posted 5 hours ago
Shares of Teva Pharmaceuticals Industries teva took a dip during trading hours Wednesday, moving as low as 6% off, after a federal agency invalidated two of the patents protecting one of its major breadwinners: Copaxone. The multiple sclerosis... Read more
5h
Fortune
Mylan CEO Heather Bresch Is in the Hot Seat Over EpiPen Price HikesBresch became CEO, it has often been unclear just who is pulling the strings at
Mylan CEO Heather Bresch Is in the Hot Seat Over EpiPen Price Hikes
Fortune / Posted 5 hours ago
Bresch became CEO, it has often been unclear just who is pulling the strings at Mylan. Last year, when Israeli drug maker Teva Pharmaceutical mounted a hostile takeover attempt, it was Coury who acted as Mylan’s mouthpiece, baiting the other... Read more
7 related stories
6h
CNBC
Shares of Teva Pharmaceuticals fall after US Patent Office invalidates two patentsto Copaxone 40 mg. The two patents invalidated on Wednesday are owned by Yeda R
Shares of Teva Pharmaceuticals fall after US Patent Office invalidates two patents
CNBC / Posted 6 hours ago
to Copaxone 40 mg. The two patents invalidated on Wednesday are owned by Yeda Research & Development and licensed to Teva. The involved parties are still waiting on a ruling for a third patent, which is expected by Sept. 1. Earlier this... Read more
6h
Business Wire
Teva Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE® 40 mgJERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE:
Teva Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE® 40 mg
Business Wire / Posted 6 hours ago
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed the Patent Trial and Appeal Board (PTAB) decisions from an Inter Partes Review (IPR) to invalidate all claims of the ‘250 and ‘413 patents for 40 mg... Read more
6h
FOX Business
Why Momenta Pharmaceuticals Shares Made a Late-Day Jump HigherThe come-from-behind victory for the day stems from a patent trial and appeal b
Why Momenta Pharmaceuticals Shares Made a Late-Day Jump Higher
FOX Business / Posted 6 hours ago
The come-from-behind victory for the day stems from a patent trial and appeal board ruling that claims 1-20 of a patent on Teva Pharmaceutical Industries' (NYSE: TEVA) three-times-weekly version of its multiple sclerosis drug Copaxone weren't... Read more
6h
FOX Business
Why Momenta Pharmaceuticals Shares Made a Late-Day Jump HigherThe come-from-behind victory for the day stems from a patent trial and appeal b
Why Momenta Pharmaceuticals Shares Made a Late-Day Jump Higher
FOX Business / Posted 6 hours ago
The come-from-behind victory for the day stems from a patent trial and appeal board ruling that claims 1-20 of a patent on Teva Pharmaceutical Industries' (NYSE: TEVA) three-times-weekly version of its multiple sclerosis drug Copaxone weren't... Read more
8h
KMGH 7 Denver
Hillary Clinton calls EpiPen maker's price increases 'outrageous'has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
Hillary Clinton calls EpiPen maker's price increases 'outrageous'
KMGH 7 Denver / Posted 8 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
8h
ABC Action News Tampa Bay
Hillary Clinton calls EpiPen maker's price increases 'outrageous'has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
Hillary Clinton calls EpiPen maker's price increases 'outrageous'
ABC Action News Tampa Bay / Posted 8 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
8h
KTNV Las Vegas
Hillary Clinton calls EpiPen maker's price increases 'outrageous'has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
Hillary Clinton calls EpiPen maker's price increases 'outrageous'
KTNV Las Vegas / Posted 8 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
8h
NBC26 Green Bay
Hillary Clinton calls EpiPen maker's price increases 'outrageous'has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
Hillary Clinton calls EpiPen maker's price increases 'outrageous'
NBC26 Green Bay / Posted 8 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
8h
KIVI Boise
Hillary Clinton calls EpiPen maker's price increases 'outrageous'has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
Hillary Clinton calls EpiPen maker's price increases 'outrageous'
KIVI Boise / Posted 8 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
8h
WRTV Indianapolis
Hillary Clinton calls EpiPen maker's price increases 'outrageous'has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
Hillary Clinton calls EpiPen maker's price increases 'outrageous'
WRTV Indianapolis / Posted 8 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
9h
KGTV San Diego
Hillary Clinton calls EpiPen maker's price increases 'outrageous'has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
Hillary Clinton calls EpiPen maker's price increases 'outrageous'
KGTV San Diego / Posted 9 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
10h
The Mercury News
EpiPen's soaring price: It now costs $300, and people are angryhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
EpiPen's soaring price: It now costs $300, and people are angry
The Mercury News / Posted 10 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
12h
FOX News
Epipen was Mylan CEO's 'baby': Now she's in the hot seatBresch became CEO, it has often been unclear just who is pulling the strings at
Epipen was Mylan CEO's 'baby': Now she's in the hot seat
FOX News / Posted 12 hours ago
Bresch became CEO, it has often been unclear just who is pulling the strings at Mylan. Last year, when Israeli drug maker Teva Pharmaceutical mounted a hostile takeover attempt, it was Coury who acted as Mylan’s mouthpiece, baiting the other... Read more
7 related stories
12h
FOX News
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
FOX News / Posted 12 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
12h
Market Watch
Congress joins fight over rising cost of EpiPens as Shkreli defendsas the company gained market share, due to similar products, the Auvi-Q from Sa
Congress joins fight over rising cost of EpiPens as Shkreli defends
Market Watch / Posted 12 hours ago
as the company gained market share, due to similar products, the Auvi-Q from Sanofi US, recalled in the fall of 2015 and Teva failing to gain approval for its generic drug earlier this year. “Not only should the Judiciary Committee hold a... Read more
225 related stories
13h
Newsmax
How EpiPen's Maker Raised Prices, and Hackles, So Muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's Maker Raised Prices, and Hackles, So Much
Newsmax / Posted 13 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
13h
Calgary Sun
How EpiPen's maker raised priceshas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices
Calgary Sun / Posted 13 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
14h
CBS Baltimore
How EpiPen's Maker Raised Prices, And Hackles, So Muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's Maker Raised Prices, And Hackles, So Much
CBS Baltimore / Posted 14 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn’t gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
15h
NBC News
How Mylan hiked prices of lots of other products besides lifesaving EpiPenrecall last year of Sanofi's competing product Auvi-Q, and the denial of regula
How Mylan hiked prices of lots of other products besides lifesaving EpiPen
NBC News / Posted 15 hours ago
recall last year of Sanofi's competing product Auvi-Q, and the denial of regulatory approval for a generic competitor from Teva. "I think we're seeing a classic scenario that we see in the drug world, which is less competition equals higher... Read more
225 related stories
15h
The News & Observer
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
The News & Observer / Posted 15 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
16h
FOX Business
EpiPen Price Gouging Came As Mylan Pulled Off Tax Inversionby the companies who hold the patents. As patents expire, generic drug companie
EpiPen Price Gouging Came As Mylan Pulled Off Tax Inversion
FOX Business / Posted 16 hours ago
by the companies who hold the patents. As patents expire, generic drug companies often jump in. But oddly, Israeli-based Teva Pharmaceuticals (NYSE:TEVA) attempted to present a generic version but was soundly swatted down by the FDA which cited... Read more
7 related stories
16h
FOX Business
EpiPen Price Gouging Came As Mylan Pulled Off Tax Inversionby the companies who hold the patents. As patents expire, generic drug companie
EpiPen Price Gouging Came As Mylan Pulled Off Tax Inversion
FOX Business / Posted 16 hours ago
by the companies who hold the patents. As patents expire, generic drug companies often jump in. But oddly, Israeli-based Teva Pharmaceuticals (TEVA) attempted to present a generic version but was soundly swatted down by the FDA which cited... Read more
7 related stories
20h
FOX Business
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
FOX Business / Posted 20 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
20h
FOX Business
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
FOX Business / Posted 20 hours ago
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
Lisbon Morning Journal
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
Lisbon Morning Journal / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
The Marietta Times
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
The Marietta Times / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
The Seattle Times
As EpiPen prices rocket up, lawmakers demand answersUnfortunately, they were found to give potentially improper doses, and were pul
As EpiPen prices rocket up, lawmakers demand answers
The Seattle Times / Posted yesterday
Unfortunately, they were found to give potentially improper doses, and were pulled from the shelves about a year ago. Teva had hoped to offer a generic version of the EpiPen, but concerns from the FDA sent it back to the drawing board until at... Read more
225 related stories
1d
Marshalltown Times-Republican
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
Marshalltown Times-Republican / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
CTV News
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
CTV News / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
FOX Business
3 Stocks Billionaires Are Buyingdebt load. Recently, Allergan's shares have been rallying following the comple
3 Stocks Billionaires Are Buying
FOX Business / Posted yesterday
debt load. Recently, Allergan's shares have been rallying following the completion of the sale of its generics business to Teva Pharmaceutical Industries. Allergan walked away from that sale with$33.4 billionin cash and 100.3 million shares of Teva... Read more
1d
FOX Business
3 Stocks Billionaires Are Buyingdebt load. Recently, Allergan's shares have been rallying following the comple
3 Stocks Billionaires Are Buying
FOX Business / Posted yesterday
debt load. Recently, Allergan's shares have been rallying following the completion of the sale of its generics business to Teva Pharmaceutical Industries. Allergan walked away from that sale with$33.4 billionin cash and 100.3 million shares of Teva... Read more
1d
International Business Times
Congress members call for investigation into Mylan for 'outrageous' price hike of the EpiPenmedication's injectors. PBS NewsHour reported that Sanofi was forced to recall
Congress members call for investigation into Mylan for 'outrageous' price hike of the EpiPen
International Business Times / Posted yesterday
medication's injectors. PBS NewsHour reported that Sanofi was forced to recall its own injector due to dosing issues, while Teva Pharmaceuticals was unable to win regulatory approval for its injector last spring. A generic version, called... Read more
14 related stories
1d
The Sacramento Bee
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
The Sacramento Bee / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
Santa Cruz Sentinel
How EpiPen’s maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen’s maker raised prices, and hackles, so much
Santa Cruz Sentinel / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn’t gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
Spartanburg Herald-Journal
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
Spartanburg Herald-Journal / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
The Hendersonville Times-News
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
The Hendersonville Times-News / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
KXXV Waco
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
KXXV Waco / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
FOX 8 New Orleans
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
FOX 8 New Orleans / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
KPLC Lake Charles
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
KPLC Lake Charles / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
KWWL Iowa
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
KWWL Iowa / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
WCAX-TV Vermont
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
WCAX-TV Vermont / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
The Register NorthJersey.com
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
The Register NorthJersey.com / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn’t gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
WBOC Salisbury
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
WBOC Salisbury / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
1d
WFMJ Youngstown
How EpiPen's maker raised prices, and hackles, so muchhas a U.S. patent giving it a monopoly until 2025, according to Evercore ISI an
How EpiPen's maker raised prices, and hackles, so much
WFMJ Youngstown / Posted yesterday
has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was... Read more
225 related stories
More

People in this news